Literature DB >> 28192258

Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.

Majid Sheykhzade1, Nilofar Amandi2, Monica Vidal Pla2, Bahareh Abdolalizadeh2, Anette Sams3, Karin Warfvinge3, Lars Edvinsson3, Darryl S Pickering2.   

Abstract

AIM: The neuropeptide calcitonin gene-related peptide (CGRP) is found in afferent sensory nerve fibers innervating the resistance arteries and plays a pivotal role in a number of neurovascular diseases such as migraine and subarachnoid bleedings. The present study investigates the binding and antagonistic characteristics of small non-peptide CGRP receptor antagonists (i.e. gepants) in isolated rat brain and mesenteric resistance arteries.
METHODS: The antagonistic behavior of gepants was investigated in isolated rat mesenteric arteries using a wire myograph setup while binding of gepants to CGRP receptors was investigated in rat brain membranes using a radioligand competitive binding assay. Furthermore, the histological location of the key components of CGRP receptor (RAMP1 and CLR) was assessed by immunohistochemistry.
RESULTS: Our functional studies clearly show that all gepants are reversible competitive antagonists producing Schild plot slopes not significantly different from unity and thus suggesting presence of a uniform CGRP receptor population in the arteries. A uniform receptor population was also confirmed by radioligand competitive binding studies showing similar affinities for the gepants in rat brain and mesenteric arteries, the exception being rimegepant which had 50-fold lower affinity in brain than mesenteric arteries. CLR and RAMP1 were shown to be located in both vascular smooth muscle and endothelial cells of rat mesenteric arteries by immunohistochemistry.
CONCLUSION: The present results indicate that, despite species differences in the CGRP receptor affinity, the antagonistic nature of these gepants, the distribution pattern of CGRP receptor components and the mechanism behind CGRP-induced vasodilation seem to be similar in resistance-sized arteries of human and rats.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Binding affinity; Brain; CGRP receptor; Gepants; Mesenteric arteries; Schild plot

Mesh:

Substances:

Year:  2017        PMID: 28192258     DOI: 10.1016/j.vph.2017.02.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  5 in total

Review 1.  Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.

Authors:  Debbie L Hay; Michael L Garelja; David R Poyner; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-11-28       Impact factor: 8.739

2.  Rimegepant for the treatment of migraine.

Authors:  Amnon A Berger; Ariel Winnick; Austin H Carroll; Alexandra Welschmeyer; Nathan Li; Marc Colon; Antonella Paladini; Giovanni F Ramírez; Jamal Hasoon; Elyse M Cornett; Jaehong Song; Giustino Varrassi; Adam M Kaye; Alan D Kaye; Latha Ganti
Journal:  Health Psychol Res       Date:  2022-10-12

3.  Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity.

Authors:  Jing Zhu; Mahdieh Dagina Pedersen; Laraib Sabbah Ahmed; Bahareh Abdolalizadeh; Anne-Sofie Grell; Jais Oliver Berg; Peter Waaben Thulstrup; Henrik Franzyk; Lars Edvinsson; Anette Sams; Majid Sheykhzade; Paul Robert Hansen
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

Review 4.  Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.

Authors:  Fred Cohen; Hsiangkuo Yuan
Journal:  Ther Clin Risk Manag       Date:  2022-04-22       Impact factor: 2.755

5.  Myocardial perfusion recovery induced by an α-calcitonin gene-related peptide analogue.

Authors:  Simon Bentsen; Anette Sams; Philip Hasbak; Lars Edvinsson; Andreas Kjaer; Rasmus S Ripa
Journal:  J Nucl Cardiol       Date:  2021-06-04       Impact factor: 3.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.